US 6,649,599 B2 · Methods and compositions for poly-β-1-4-N-acetylglucosamine cell therapy system

Abstract

The present invention relates to a purified, easily produced poly-β-1→4-N-acetylglucosamine (p-GlcNAc) polysaccharide species. The p-GlcNAc of the invention is a polymer of high molecular weight whose constituent monosaccharide sugars are attached in a β-1→4 conformation, and which is free of proteins, and substantially free of single amino acids, and other organic and inorganic contaminants. In addition, derivatives and reformulations of p-GlcNAc are described. The present invention further relates to methods for the purification of the p-GlcNAc of the invention from microalgae, preferably diatom, starting sources. Still further, the invention relates to methods for the derivatization and reformulation of the p-GlcNAc. Additionally, the present invention relates to the uses of pure p-GlcNAc, its derivatives, and/or its reformulations.

Claims4

Dependent claims

A pharmaceutical composition comprising a therapeutically effective amount of a microalgal poly-β-1→4-N-acetylglucosamine, or a derivative thereof, and a pharmaceutically acceptable carrier.

Dependencies are inferred from the claim text.

Facts

Application

10/005,130Filed 5 Dec 2001 · continuation

Priority

1 Dec 1993

Published

US 2002/0106792 A18 Aug 2002

Granted

18 Nov 2003

Term ends

Not estimatedThe source records don’t support an estimate.

Classification23 codes

C12N 1/125
Unicellular algae; Culture media therefor: unicellular algae isolates
A61K 9/205
Organic macromolecular compounds: polysaccharides, e.g. alginate, gums; Cyclodextrin
A61K 47/61
The modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule: the organic macromolecular…
A61K 47/69
The non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates: the conjugate being characterised by…

Family

Application08/160,569Parent of this continuation-in-part · filed 1 Dec 1993

Application08/347,911Parent of this continuation-in-part · filed 1 Dec 1994

Application08/471,290Parent of this division · filed 6 Jun 1995

Application09/227,840Parent of this continuation · filed 11 Jan 1999

Application09/866,827Parent of this continuation · filed 29 May 2001

US 2002/0106792 A1Pre-grant publication · published 8 Aug 2002

Application09/227,840Parent of this division

US 5,858,350 AParent of this division

Application08/471,290Parent of this continuation-in-part

US 5,623,064 AParent of this continuation-in-part

US 5,622,834 AParent of this continuation-in-part

US 2001/0055807 A1Published application

US 6,610,668 B2Related patent

US 6,649,599 B2This patent

From the US filing history. Foreign family members aren’t listed.

Methods and compositions for poly-β-1-4-N-acetylglucosamine cell therapy system

Life of this patent

Methods and compositions for poly-β-1-4-N-acetylglucosamine cell therapy system

Life of this patent

Abstract

Claims4